Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingr'HIV
2023-504482-23-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Planned start Jul 2023; status: authorised.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2023-504482-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504482-23-00.